Key terms
About TMDX
TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TMDX news
May 01
11:08am ET
TransMedics Group (TMDX) Receives a Buy from Piper Sandler
May 01
11:05am ET
TransMedics price target raised to $120 from $95 at Piper Sandler
May 01
8:32am ET
TransMedics price target raised to $117 from $102 at Canaccord
May 01
8:01am ET
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), TransMedics Group (TMDX) and Incyte (INCY)
May 01
7:44am ET
TransMedics price target raised to $125 from $105 at Oppenheimer
May 01
7:29am ET
TransMedics price target raised to $130 from $100 at TD Cowen
Apr 30
4:07pm ET
TransMedics raises FY24 revenue view to $390M-$400M from $360M-$370M
Apr 30
4:07pm ET
TransMedics reports Q1 EPS 35c, consensus (5c)
Apr 03
8:01am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Apr 02
4:55am ET
TransMedics management to meet with Oppenheimer
Mar 28
9:52am ET
Palantir downgraded, CyberArk initiated: Wall Street’s top analyst calls
Mar 28
5:16am ET
TransMedics initiated with an Overweight at Piper Sandler
Mar 27
4:26pm ET
TransMedics management to meet with Oppenheimer
Mar 25
6:25am ET
TransMedics Group: Operational Efficiency and Market Positioning Propel Buy Rating
Mar 15
10:56am ET
TransMedics participates in a conference call with JPMorgan
Feb 27
8:30am ET
TransMedics price target raised to $102 from $96 at Canaccord
Feb 27
7:48am ET
Oppenheimer Sticks to Its Buy Rating for TransMedics Group (TMDX)
Feb 27
7:38am ET
TransMedics price target raised to $105 from $92 at Oppenheimer
Feb 27
6:30am ET
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX), TransMedics Group (TMDX) and MoonLake Immunotherapeutics (MLTX)
Feb 26
4:09pm ET
TransMedics sees FY24 revenue $360M-$370M, consensus $330.23M
Feb 26
4:09pm ET
TransMedics reports Q4 EPS 12, consensus (3c)
Feb 07
4:43am ET
TransMedics Expands Fleet for National OCS Program
Feb 05
4:05pm ET
Buy Rating on TransMedics Group Amidst Growing Organ Transplant Market
No recent press releases are available for TMDX
TMDX Financials
Key terms
Ad Feedback
TMDX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TMDX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
